Paul Miller has joined Artizan Biosciences as chief scientific officer, the same position he held at Synlogic (NASDAQ: [[ticker:SYBX]]). Miller’s experience also includes senior roles at AstraZeneca (NYSE: [[ticker:AZN]]) and Pfizer (NYSE: [[ticker:PFE]]). New Haven, CT-based Artizan Bio, a spinout of Yale University, is developing drugs that target the gut microbiome.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
